Success sugars the biotech pill

Article Abstract:

Biotechnology firms in the UK are showing significant growth. A number of them have already started to seek listing in the very discriminating London Stock Exchange. One of the very few that have succeeded is Oxford-based British Biotechnology which is currently capitalized at 150 million pounds sterling. Other firms awaiting floatation in the near future include Cantab Pharmaceuticals, Xenova, Ethical Holdings and Celltech. Getting listed in the London Stock Exchange is generally difficult for biotechnology companies because the bourse prefers firms with a history of strong performance. Another difficulty presented by the entry of biotechnology firms into the stock market is the complexity of these firms' accounts. They are likely to have highly volatile stock market performances, but could make large sums of money for shareholders if any of these firms succeed in introducing a revolutionary drug.

Biological products exc. diagnostic, Diagnostic substances, Biotechnology industry, Biotechnology industries, Column

---

Scots to the rescue

Article Abstract:

The appointment of Scottish accountants and executives by London-based companies to carry out corporate rescue missions characterizes the achievements of Scottish accountancy and management. Among the Scots appointed to top positions at struggling companies are James MacAdam as chairman of jewelry firm Raetners, Murray Stuart at failing property group Berisford, Ken Scobie at debt-ridden Brent Walker, and Nigel Turnbull as chief executive of the London office of the market firm Rosehaugh. The reason behind the appointment of Scots, although partly cultural, is largely due to the strong acquittal of the Scottish finance industry of itself in previous years. This high demand for Scottish accountancy and management however is unlikely to last given that not all Scots in London performed well in the recession.

Scotland, Recruiting, Employment, Corporations, Accountants, Corporations, British, Scots, Scots (British people)

---

Chemical reaction

Article Abstract:

Manufacturing conglomerate Grampian Holdings PLC is faced with the challenge of reestablishing its financial standing in the Scottish business community following its failed takeover of the pharmaceutical company Macarthy PLC. Grampian's 79-million-pounds-sterling bid for Macarthy elicited anti-takeover measures from the chemist company in the form of a document intended to raise doubts regarding Grampian's accounting treatments. City supporters discount the accuracy of these claims and remain confident in the conglomerate's financial capabilities. Grampian is relying on the Mar 1992 figures for profits to dispel any lingering doubts regarding the stability of the company.

Pharmaceutical preparations, Management, Conglomerate corporations, Pharmaceutical industry, Mergers, acquisitions and divestments, Acquisitions and mergers, Macarthy PLC, Corporate anti-takeover measures, Antitakeover strategies, Grampian Holdings PLC

Similar abstracts:

• Abstracts: Brewers loosen the old school tie. Capitalists and their ventures. Good going for the big bookie
• Abstracts: Fare wars forever. Clipping ads to boost service
• Abstracts: Tasty toothpastes and sensitive brushes. What's in the cornucopia: new products at FMI. The greening of cleaning
• Abstracts: Safeguard's risky mission. Empowered by Enrico. Campaign 1992 is open for business

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.